pharmaceutical industry – The Milli Chronicle

Monday, January 5, 2026

Latest:

Investors Brace for Renewed Market Turbulence After US Action in Venezuela
Trump Signals Tough Stance on Venezuela as Global Attention Focuses on Leadership Transition
Teen Victims Identified as Switzerland Mourns Deadly New Year’s Eve Bar Fire
Yemeni Government Warns of Action as Tensions Rise Over Aden Access Restrictions
North Korea Missile Launches Add to Global Tensions Amid Venezuela Crisis and Regional Diplomacy

Factual Version of a Story

NewsDesk Milli Chronicle January 1, 2026 branded medicines market, cancer drug market, diabetes medication pricing, drug affordability debate, drug pricing reform, drugmaker pricing strategy, healthcare innovation, healthcare policy US, inflation and drug prices, medical research investment, medicine pricing updates, patient access medicines, pharmaceutical industry, pharmaceutical regulation, pharmaceutical trends 2026, prescription drugs USA, US drug prices, US healthcare economy, US medicine costs, vaccine pricing news

Drugmakers Adjust US Medicine Prices While Expanding Innovation and Access Efforts

Measured price updates across select medicines highlight the pharmaceutical industry’s balancing act between affordability, innovation, and long-term investment in patient

Novo Nordisk and Eli Lilly Reject Claims of Partnership with Mangoceuticals on Obesity Drugs

Novo Nordisk and Eli Lilly clarify that they have no collaboration or special arrangement with telehealth firm Mangoceuticals, following misleading

Novo Nordisk’s New Power Lineup: A Fresh Era of Leadership and Strategy

Novo Nordisk ushers in a new leadership team blending deep industry experience, scientific excellence, and strategic vision. In a move